FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately.

Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013.



Teva Pharmaceutical Industries Ltd. 


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Hot spots where covid vaccination lags push experimental antibody treatment